Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Two Sigma Advisers LP

Two Sigma Advisers LP raised its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 649.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,021,700 shares of the company's stock after purchasing an additional 885,300 shares during the period. Two Sigma Advisers LP's holdings in Novo Nordisk A/S were worth $87,887,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Center for Financial Planning Inc. grew its stake in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL grew its stake in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after acquiring an additional 300 shares during the last quarter. Transce3nd LLC purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $33,000. Kelly Lawrence W & Associates Inc. CA purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $39,000. Finally, Albion Financial Group UT grew its stake in shares of Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after acquiring an additional 278 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Down 0.0%

NYSE:NVO traded down $0.01 during trading hours on Wednesday, hitting $68.19. The company had a trading volume of 8,954,330 shares, compared to its average volume of 6,659,274. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average of $67.00 and a 200 day moving average of $83.76. The company has a market cap of $306.02 billion, a P/E ratio of 20.73, a P/E/G ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Morgan Stanley began coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an "equal weight" rating on the stock. StockNews.com raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. BNP Paribas initiated coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an "underperform" rating for the company. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Stifel Nicolaus downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Moderate Buy" and a consensus price target of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.